By Ryan Whitwam
While antibiotics have given humanity a powerful tool to fight pathogenic bacteria, viruses
have proven a much more stubborn enemy. Vaccination has proven
effective for many diseases, but they are harder to produce and usually
must be administered in advance of infection. Researchers at Stanford
have identified a previously abandoned drug that might shut down the
ability of some viruses to infect cells and reproduce. There is hope
this drug could help fight some of the most serious public health
threats today including ebola, dengue, and zika.
Viruses are
notoriously hard to fight largely because of their simplicity. Most of
them are protein shells with a few receptors filled with genetic
material. All they do is infiltrate cells, make more genetic material,
and repeat. Even when we can develop vaccines, some viruses mutate so
quickly that you won’t be protected for long (eg. influenza). This
approach of focusing on a single virus at a time does yield results, but
a drug that could combat many of them (more akin to antibiotics) would
be ideal.
The Stanford team was
made aware of a molecule that was studied at GlaxoSmithKline some years
ago. It seemed to have good efficacy against a number of RNA viruses,
but it was shelved. This is important because many of the dangerous
viruses that are keeping medical staff busy are RNA-based — that is,
they store their genetic information as RNA rather than DNA like most
organisms do. When tested in human cell cultures, this as-yet unnamed
drug is able to protect cells from Venezuelan equine encephalitis virus (VEEV) and dengue, both of which usually kill the cells. However, it also affected the human cells’ ability to divide.
To understand what
the drug was doing, the team had to figure out what molecule it was
inhibiting. Using advanced genetic screening techniques, they learned
that the drug blocks the activity of a protein that is crucial for
generating building blocks of RNA. That explains why the viruses were
unable to replicate and kill the human cells, but it also helped the
researchers devise some possible solutions to the side effects.
The same genetic
building blocks that are needed for RNA synthesis are needed for DNA
synthesis. So, it makes sense that the human cells in culture would be
unable to divide — they can’t replicate their genome for the new cell.
To compensate, the team supplied cells with different precursors that
could be used to make DNA, but not RNA. This effectively shuts the virus
out from being able to create more copies of itself, while allowing the
human cell to divide normally.
The team is careful
to point out this has only been shown to work in vitro. Giving this drug
to a live person is still a long way off. Our cells use RNA in various
ways as well, so there could be long-term issues from this drug.
However, the side effects might be mild, and we are talking about
life-threatening diseases. The risk might be worth it.
Post a Comment